Advanced search
Publication Cover
Future Neurology Volume 7, 2012 - Issue 6
Submit an article Journal homepage
149
Views
0
CrossRef citations to date
0
Altmetric
Review

A Critical Kinase Cascade In Neurological Disorders: Pi3K, Akt and Mtor

Zhao Zhong Chong1 Laboratory of Cellular & Molecular Signaling, Cancer Center, F 1220, New Jersey Health Sciences University, 205 South Orange Avenue, Newark, NJ07101, USA;2 New Jersey Health Sciences University, Newark, NJ07101, USAView further author information
,
Yan Chen Shang1 Laboratory of Cellular & Molecular Signaling, Cancer Center, F 1220, New Jersey Health Sciences University, 205 South Orange Avenue, Newark, NJ07101, USA;2 New Jersey Health Sciences University, Newark, NJ07101, USAView further author information
,
Shaohui Wang1 Laboratory of Cellular & Molecular Signaling, Cancer Center, F 1220, New Jersey Health Sciences University, 205 South Orange Avenue, Newark, NJ07101, USA;2 New Jersey Health Sciences University, Newark, NJ07101, USAView further author information
&
Kenneth Maiese1 Laboratory of Cellular & Molecular Signaling, Cancer Center, F 1220, New Jersey Health Sciences University, 205 South Orange Avenue, Newark, NJ07101, USA;2 New Jersey Health Sciences University, Newark, NJ07101, USA;3 Cancer Institute of New Jersey, NJ, USA.Correspondence[email protected]
View further author information
Pages 733-748 | Published online: 07 Nov 2012

References

  • Chong ZZ , MaieseK. The Src homology 2 domain tyrosine phosphatases SHP-1 and SHP-2: diversified control of cell growth, inflammation, and injury. Histol. Histopathol.22(11), 1251–1267 (2007).
  • Lopez-Ruiz P , Rodriguez-UbrevaJ, CariagaAE, CortesMA, ColasB. SHP-1 in cell-cycle regulation. Anticancer Agents Med. Chem.11(1), 89–98 (2011).
  • Chong ZZ , LiF, MaieseK. Activating Akt and the brain‘s resources to drive cellular survival and prevent inflammatory injury. Histol. Histopathol.20(1), 299–315 (2005).
  • Cheng Z , WhiteMF. Targeting Forkhead box O1 from the concept to metabolic diseases: lessons from mouse models. Antioxid. Redox Signal14(4), 649–661 (2011).
  • Datta SR , BrunetA, GreenbergME. Cellular survival: a play in three Akts. Genes Dev.13(22), 2905–2927. (1999).
  • Chong ZZ , ShangYC, ZhangL, WangS, MaieseK. Mammalian target of rapamycin: hitting the bull‘s-eye for neurological disorders. Oxid. Med. Cell Longev.3(6), 374–391 (2010).
  • Huang X , ZhangH, YangJet al. Pharmacological inhibition of the mammalian target of rapamycin pathway suppresses acquired epilepsy. Neurobiol. Dis.40(1), 193–199 (2010).
  • Chong ZZ , MaieseK. Mammalian target of rapamycin signaling in diabetic cardiovascular disease. Cardiovasc. Diabetol.11(1), 45 (2012).
  • Reynolds THT , BodineSC, LawrenceJC Jr. Control of Ser2448 phosphorylation in the mammalian target of rapamycin by insulin and skeletal muscle load. J. Biol. Chem.277(20), 17657–17662 (2002).
  • Scott PH , BrunnGJ, KohnAD, RothRA, LawrenceJC Jr. Evidence of insulin-stimulated phosphorylation and activation of the mammalian target of rapamycin mediated by a protein kinase B signaling pathway. Proc. Natl Acad. Sci. USA95(13), 7772–7777 (1998).
  • Soliman GA , Acosta-JaquezHA, DunlopEAet al. mTOR Ser-2481 autophosphorylation monitors mTORC-specific catalytic activity and clarifies rapamycin mechanism of action. J. Biol. Chem.285(11), 7866–7879 (2010).
  • Ekim B , MagnusonB, Acosta-JaquezHA, KellerJA, FeenerEP, FingarDC. mTOR kinase domain phosphorylation promotes mTORC1 signaling, cell growth, and cell cycle progression. Mol. Cell Biol.31(14), 2787–2801 (2011).
  • Chong ZZ , ShangYC, WangS, MaieseK. Shedding new light on neurodegenerative diseases through the mammalian target of rapamycin. Prog. Neurobiol. doi:10.1016/j.pneurobio.2012.08.001 (2012) (Epub ahead of print).
  • Loewith R , JacintoE, WullschlegerSet al. Two TOR complexes, only one of which is rapamycin sensitive, have distinct roles in cell growth control. Mol. Cell10(3), 457–468 (2002).
  • Chong ZZ , ShangYC, MaieseK. Cardiovascular disease and mTOR signaling. Trends Cardiovasc. Med.21(5), 151–155 (2011).
  • Sehgal SN , BakerH, VezinaC. Rapamycin (AY-22,989), a new antifungal antibiotic. II. Fermentation, isolation and characterization. J. Antibiot. (Tokyo)28(10), 727–732 (1975).
  • Vezina C , KudelskiA, SehgalSN. Rapamycin (AY-22,989), a new antifungal antibiotic. I. Taxonomy of the producing streptomycete and isolation of the active principle. J. Antibiot. (Tokyo)28(10), 721–726 (1975).
  • Sarbassov DD , AliSM, SenguptaSet al. Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB. Mol. Cell22(2), 159–168 (2006).
  • Takahashi T , HaraK, InoueHet al. Carboxyl-terminal region conserved among phosphoinositide-kinase-related kinases is indispensable for mTOR function in vivo and in vitro. Genes Cells5(9), 765–775 (2000).
  • Chen J , ZhengXF, BrownEJ, SchreiberSL. Identification of an 11-kDa FKBP12-rapamycin-binding domain within the 289-kDa FKBP12-rapamycin-associated protein and characterization of a critical serine residue. Proc. Natl Acad. Sci. USA92(11), 4947–4951 (1995).
  • Abraham RT . mTOR as a positive regulator of tumor cell responses to hypoxia. Curr. Topic. Microbiol. Immunol.279, 299–319 (2004).
  • Takahara T , HaraK, YonezawaK, SorimachiH, MaedaT. Nutrient-dependent multimerization of the mammalian target of rapamycin through the N-terminal HEAT repeat region. J. Biol. Chem.281(39), 28605–28614 (2006).
  • Wang H , ZhangQ, WenQet al. Proline-rich Akt substrate of 40kDa (PRAS40). a novel downstream target of PI3k/Akt signaling pathway. Cell Signal.24(1), 17–24 (2012).
  • Wang L , HarrisTE, RothRA, LawrenceJC Jr. PRAS40 regulates mTORC1 kinase activity by functioning as a direct inhibitor of substrate binding. J. Biol. Chem.282(27), 20036–20044 (2007).
  • Kim DH , SarbassovDD, AliSMet al. GbetaL, a positive regulator of the rapamycin-sensitive pathway required for the nutrient-sensitive interaction between raptor and mTOR. Mol. Cell11(4), 895–904 (2003).
  • Peterson TR , LaplanteM, ThoreenCCet al. DEPTOR is an mTOR inhibitor frequently overexpressed in multiple myeloma cells and required for their survival. Cell137(5), 873–886 (2009).
  • Fingar DC , RichardsonCJ, TeeAR, CheathamL, TsouC, BlenisJ. mTOR controls cell cycle progression through its cell growth effectors S6K1 and 4E-BP1/eukaryotic translation initiation factor 4E. Mol. Cell Biol.24(1), 200–216 (2004).
  • Jastrzebski K , HannanKM, TchoubrievaEB, HannanRD, PearsonRB. Coordinate regulation of ribosome biogenesis and function by the ribosomal protein S6 kinase, a key mediator of mTOR function. Growth Factors25(4), 209–226 (2007).
  • Gingras AC , KennedySG, O‘LearyMA, SonenbergN, HayN. 4E-BP1, a repressor of mRNA translation, is phosphorylated and inactivated by the Akt(PKB) signaling pathway. Genes Dev.12(4), 502–513 (1998).
  • Bhandari BK , FeliersD, DuraisamySet al. Insulin regulation of protein translation repressor 4E-BP1, an eIF4E-binding protein, in renal epithelial cells. Kidney Int.59(3), 866–875 (2001).
  • Benjamin D , ColombiM, MoroniC, HallMN. Rapamycin passes the torch: a new generation of mTOR inhibitors. Nat. Rev. Drug Discov.10(11), 868–880 (2011).
  • Jacinto E , LoewithR, SchmidtAet al. Mammalian TOR complex 2 controls the actin cytoskeleton and is rapamycin insensitive. Nat. Cell Biol.6(11), 1122–1128 (2004).
  • Rosner M , FuchsC, SiegelN, ValliA, HengstschlagerM. Functional interaction of mammalian target of rapamycin complexes in regulating mammalian cell size and cell cycle. Hum. Mol. Genet.18(17), 3298–3310 (2009).
  • Dada S , DemartinesN, DormondO. mTORC2 regulates PGE2-mediated endothelial cell survival and migration. Biochem. Biophys. Res. Commun.372(4), 875–879 (2008).
  • Sarbassov DD , AliSM, KimDHet al. Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton. Curr. Biol.14(14), 1296–1302 (2004).
  • Pearce LR , SommerEM, SakamotoK, WullschlegerS, AlessiDR. Protor-1 is required for efficient mTORC2-mediated activation of SGK1 in the kidney. Biochem. J.436(1), 169–179 (2011).
  • Garcia-Martinez JM , AlessiDR. mTOR complex 2 (mTORC2) controls hydrophobic motif phosphorylation and activation of serum- and glucocorticoid-induced protein kinase 1 (SGK1). Biochem. J.416(3), 375–385 (2008).
  • Gulhati P , BowenKA, LiuJet al. mTORC1 and mTORC2 regulate EMT, motility, and metastasis of colorectal cancer via RhoA and Rac1 signaling pathways. Cancer Res.71(9), 3246–3256 (2011).
  • Hernandez-Negrete I , Carretero-OrtegaJ, RosenfeldtHet al. P-Rex1 links mammalian target of rapamycin signaling to Rac activation and cell migration. J. Biol. Chem.282(32), 23708–23715 (2007).
  • Zou ZQ , ZhangLN, WangF, BellengerJ, ShenYZ, ZhangXH. The novel dual PI3K/mTOR inhibitor GDC-0941 synergizes with the MEK inhibitor U0126 in non-small cell lung cancer cells. Mol. Med. Report5(2), 503–508 (2012).
  • Lee G , GoretskyT, ManagliaEet al. Phosphoinositide 3-kinase signaling mediates beta-catenin activation in intestinal epithelial stem and progenitor cells in colitis. Gastroenterology139(3), 869–881, 881.e1–9 (2010).
  • Maiese K , ChongZZ, ShangYC, HouJ. Novel Avenues of Drug Discovery and Biomarkers for Diabetes Mellitus. J. Clin. Pharmacol.51(2), 128–152 (2011).
  • Ding Z , LiangJ, LiJet al. Physical association of PDK1 with AKT1 is sufficient for pathway activation independent of membrane localization and phosphatidylinositol 3 kinase. PLoS ONE5(3), e9910 (2010).
  • Glidden EJ , GrayLG, VemuruS, LiD, HarrisTE, MayoMW. Multiple site acetylation of Rictor stimulates mammalian target of rapamycin complex 2 (mTORC2)-dependent phosphorylation of Akt protein. J. Biol. Chem.287(1), 581–588 (2012).
  • Chen JX , TuoQ, LiaoDF, ZengH. Inhibition of protein tyrosine phosphatase improves angiogenesis via enhancing Ang-1/Tie-2 signaling in diabetes. Exp. Diabetes Res.2012, 836759 (2012).
  • Deblon N , BourgoinL, Veyrat-DurebexCet al. Chronic mTOR inhibition by rapamycin induces muscle insulin resistance despite weight loss in rats. Br. J. Pharmacol.165(7), 2325–2340 (2012).
  • Hou J , ChongZZ, ShangYC, MaieseK. Early apoptotic vascular signaling is determined by Sirt1 through nuclear shuttling, forkhead trafficking, bad, and mitochondrial caspase activation. Curr. Neurovasc. Res.7(2), 95–112 (2010).
  • Maiese K , ChongZZ, ShangYC. Mechanistic insights into diabetes mellitus and oxidative stress. Curr. Med. Chem.14(16), 1729–1738 (2007).
  • Saha AK , XuXJ, LawsonEet al. Downregulation of AMPK accompanies leucine- and glucose-induced increases in protein synthesis and insulin resistance in rat skeletal muscle. Diabetes59(10), 2426–2434 (2010).
  • Koshimizu T , KawaiM, KondouHet al. Vinculin functions as regulator of chondrogenesis. J. Biol. Chem.287(19), 15760–15775 (2012).
  • Lu MJ , ChenYS, HuangHS, MaMC. Erythropoietin alleviates post-ischemic injury of rat hearts by attenuating nitrosative stress. Life Sci.90(19–20), 776–784 (2012).
  • Inoki K , LiY, ZhuT, WuJ, GuanKL. TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling. Nat. Cell Biol.4(9), 648–657 (2002).
  • Sato T , NakashimaA, GuoL, TamanoiF. Specific activation of mTORC1 by Rheb G-protein in vitro involves enhanced recruitment of its substrate protein. J. Biol. Chem.284(19), 12783–12791 (2009).
  • Cai SL , TeeAR, ShortJDet al. Activity of TSC2 is inhibited by AKT-mediated phosphorylation and membrane partitioning. J. Cell Biol.173(2), 279–289 (2006).
  • Zandi E , RothwarfDM, DelhaseM, HayakawaM, KarinM. The IkappaB kinase complex (IKK) contains two kinase subunits, IKKalpha and IKKbeta, necessary for IkappaB phosphorylation and NF-kappaB activation. Cell91(2), 243–252 (1997).
  • Dan HC , AdliM, BaldwinAS. Regulation of mammalian target of rapamycin activity in PTEN-inactive prostate cancer cells by I kappa B kinase alpha. Cancer Res.67(13), 6263–6269 (2007).
  • Lee DF , KuoHP, ChenCTet al. IKK beta suppression of TSC1 links inflammation and tumor angiogenesis via the mTOR pathway. Cell130(3), 440–455 (2007).
  • Oshiro N , TakahashiR, YoshinoKet al. The proline-rich Akt substrate of 40 kDa (PRAS40) is a physiological substrate of mammalian target of rapamycin complex 1. J. Biol. Chem.282(28), 20329–20339 (2007).
  • Wang L , HarrisTE, LawrenceJC Jr. Regulation of proline-rich Akt substrate of 40 kDa (PRAS40) function by mammalian target of rapamycin complex 1 (mTORC1)-mediated phosphorylation. J. Biol. Chem.283(23), 15619–15627 (2008).
  • Sancak Y , ThoreenCC, PetersonTRet al. PRAS40 is an insulin-regulated inhibitor of the mTORC1 protein kinase. Mol. Cell25(6), 903–915 (2007).
  • Kovacina KS , ParkGY, BaeSSet al. Identification of a proline-rich Akt substrate as a 14–13–3 binding partner. J. Biol. Chem.278(12), 10189–10194 (2003).
  • Vander Haar E , LeeSI, BandhakaviS, GriffinTJ, KimDH. Insulin signalling to mTOR mediated by the Akt/PKB substrate PRAS40. Nat. Cell Biol.9(3), 316–323 (2007).
  • Maiese K . The many facets of cell injury: angiogenesis to autophagy. Curr. Neurovasc. Res.9(2), 1–2 (2012).
  • Maiese K , ChongZZ, HouJ, ShangYC. Oxidative stress: biomarkers and novel therapeutic pathways. Exp. Gerontol.45(3), 217–234 (2010).
  • Wong E , CuervoAM. Autophagy gone awry in neurodegenerative diseases. Nat. Neurosci.13(7), 805–811 (2010).
  • Gumy LF , TanCL, FawcettJW. The role of local protein synthesis and degradation in axon regeneration. Exp. Neurol.223(1), 28–37 (2010).
  • Tatton NA . Increased caspase 3 and Bax immunoreactivity accompany nuclear GAPDH translocation and neuronal apoptosis in Parkinson‘s disease. Exp. Neurol.166(1), 29–43 (2000).
  • Broe M , ShepherdCE, MilwardEA, HallidayGM. Relationship between DNA fragmentation, morphological changes and neuronal loss in Alzheimer‘s disease and dementia with Lewy bodies. Acta Neuropathol.101(6), 616–624 (2001).
  • Louneva N , CohenJW, HanLYet al. Caspase-3 is enriched in postsynaptic densities and increased in Alzheimer‘s disease. Am. J. Pathol.173(5), 1488–1495 (2008).
  • Qin AP , LiuCF, QinYYet al. Autophagy was activated in injured astrocytes and mildly decreased cell survival following glucose and oxygen deprivation and focal cerebral ischemia. Autophagy6(6), 738–753 (2010).
  • Wang JY , XiaQ, ChuKTet al. Severe global cerebral ischemia-induced programmed necrosis of hippocampal CA1 neurons in rat is prevented by 3-methyladenine: a widely used inhibitor of autophagy. J. Neuropathol. Exp. Neurol.70(4), 314–322 (2011).
  • Baba H , SakuraiM, AbeK, TominagaR. Autophagy-mediated stress response in motor neuron after transient ischemia in rabbits. J. Vasc. Surg.50(2), 381–387 (2009).
  • Canu N , TufiR, SerafinoAL, AmadoroG, CiottiMT, CalissanoP. Role of the autophagic-lysosomal system on low potassium-induced apoptosis in cultured cerebellar granule cells. J. Neurochem.92(5), 1228–1242 (2005).
  • Xue L , FletcherGC, TolkovskyAM. Autophagy is activated by apoptotic signalling in sympathetic neurons: an alternative mechanism of death execution. Mol. Cell Neurosci.14(3), 180–198 (1999).
  • Spencer B , PotkarR, TrejoMet al. Beclin 1 gene transfer activates autophagy and ameliorates the neurodegenerative pathology in alpha-synuclein models of Parkinson‘s and Lewy body diseases. J. Neurosci.29(43), 13578–13588 (2009).
  • Spilman P , PodlutskayaN, HartMJet al. Inhibition of mTOR by rapamycin abolishes cognitive deficits and reduces amyloid-beta levels in a mouse model of Alzheimer‘s disease. PLoS ONE5(4), e9979 (2010).
  • Nopparat C , PorterJE, EbadiM, GovitrapongP. The mechanism for the neuroprotective effect of melatonin against methamphetamine-induced autophagy. J. Pineal Res.49(4), 382–389 (2010).
  • Pattingre S , TassaA, QuXet al. Bcl-2 antiapoptotic proteins inhibit Beclin 1-dependent autophagy. Cell122(6), 927–939 (2005).
  • Luo S , RubinszteinDC. Apoptosis blocks Beclin 1-dependent autophagosome synthesis: an effect rescued by Bcl-xL. Cell Death Differ.17(2), 268–277 (2010).
  • Wang S , ChongZZ, ShangYC, MaieseK. WISP1 (CCN4) autoregulates its expression and nuclear trafficking of beta-catenin during oxidant stress with limited effects upon neuronal autophagy. Curr. Neurovasc. Res.9(2), 89–99 (2012).
  • Maiese K , ChongZZ, HouJ, ShangYC. The vitamin nicotinamide: translating nutrition into clinical care. Molecules14(9), 3446–3485 (2009).
  • Chong ZZ , ShangYC, WangS, MaieseK. SIRT1: New avenues of discovery for disorders of oxidative stress. Expert Opin. Ther. Targets16(2), 167–178 (2012).
  • Troy CM , AkpanN, JeanYY. Regulation of caspases in the nervous system implications for functions in health and disease. Prog. Mol. Biol. Transl. Sci.99, 265–305 (2011).
  • Maiese K , ChongZZ, ShangYC. OutFOXOing disease and disability: the therapeutic potential of targeting FoxO proteins. Trends Mol. Med.14(5), 219–227 (2008).
  • Chong ZZ , LiF, MaieseK. Oxidative stress in the brain: Novel cellular targets that govern survival during neurodegenerative disease. Prog. Neurobiol.75(3), 207–246 (2005).
  • Maiese K , ChongZZ, ShangYC, WangS. Translating cell survival and cell longevity into treatment strategies with SIRT1. Rom. J. Morphol. Embryol.52(4), 1173–1185 (2011).
  • Wang S , ChongZZ, ShangYC, MaieseK. Wnt1 inducible signaling pathway protein 1 (WISP1) blocks neurodegeneration through phosphoinositide 3 kinase/Akt1 and apoptotic mitochondrial signaling involving Bad, Bax, Bim, and Bcl-xL. Curr. Neurovasc. Res.9(1), 20–31 (2012).
  • Hou J , WangS, ShangYC, ChongZZ, MaieseK. Erythropoietin employs cell longevity pathways of SIRT1 to foster endothelial vascular integrity during oxidant stress. Curr. Neurovasc. Res.8(3), 220–235 (2011).
  • Koh PO . Nicotinamide attenuates the ischemic brain injury-induced decrease of Akt activation and Bad phosphorylation. Neurosci. Lett.498(2), 105–109 (2011).
  • Dormond O , MadsenJC, BriscoeDM. The effects of mTOR-Akt interactions on anti-apoptotic signaling in vascular endothelial cells. J. Biol. Chem.282(32), 23679–23686 (2007).
  • Chong ZZ , HouJ, ShangYC, WangS, MaieseK. EPO relies upon novel signaling of wnt1 that requires Akt1, Foxo3a, GSK-3beta, and beta-catenin to foster vascular integrity during experimental diabetes. Curr. Neurovasc. Res.8(2), 103–120 (2011).
  • Chong ZZ , LiF, MaieseK. The pro-survival pathways of mTOR and protein kinase B target glycogen synthase kinase-3beta and nuclear factor-kappaB to foster endogenous microglial cell protection. Int. J. Mol. Med.19(2), 263–272 (2007).
  • Shang YC , ChongZZ, WangS, MaieseK. Prevention of beta-amyloid degeneration of microglia by erythropoietin depends on Wnt1, the PI 3-K/mTOR pathway, Bad, and Bcl-xL. Aging (Albany NY)4(3), 187–201 (2012).
  • Choi KC , KimSH, HaJY, KimST, SonJH. A novel mTOR activating protein protects dopamine neurons against oxidative stress by repressing autophagy related cell death. J. Neurochem.112(2), 366–376 (2010).
  • Chong ZZ , ShangYC, WangS, MaieseK. PRAS40 is an integral regulatory component of erythropoietin mTOR signaling and cytoprotection. PLoS ONE7(9), e45456 (2012).
  • Shang YC , ChongZZ, WangS, MaieseK. wnt1 inducible signaling pathway protein 1 (WISP1) targets PRAS40 to govern beta-amyloid apoptotic injury of microglia. Curr. Neurovasc. Res. (2012).
  • Thedieck K , PolakP, KimMLet al. PRAS40 and PRR5-like protein are new mTOR interactors that regulate apoptosis. PLoS ONE2(11), e1217 (2007).
  • Pastor MD , Garcia-YebenesI, FradejasNet al. mTOR/S6 kinase pathway contributes to astrocyte survival during ischemia. J. Biol. Chem.284(33), 22067–22078 (2009).
  • Wu X , ReiterCE, AntonettiDA, KimballSR, JeffersonLS, GardnerTW. Insulin promotes rat retinal neuronal cell survival in a p70S6K-dependent manner. J. Biol. Chem.279(10), 9167–9175 (2004).
  • Maiese K , ChongZZ, ShangYC. Raves and risks for erythropoietin. Cytokine Growth Factor Rev.19(2), 145–155 (2008).
  • Kim J , JungY, SunHet al. Erythropoietin mediated bone formation is regulated by mTOR signaling. J. Cell Biochem.113(1), 220–228 (2012).
  • Shang YC , ChongZZ, WangS, MaieseK. Erythropoietin and Wnt1 govern pathways of mTOR, Apaf-1, and XIAP in inflammatory microglia. Curr. Neurovasc. Res.8(4), 270–285 (2011).
  • Chong ZZ , LiF, MaieseK. Attempted cell cycle induction in post-mitotic neurons occurs in early and late apoptotic programs through Rb, E2f1, and caspase 3. Curr. Neurovasc. Res.3(1), 25–39 (2006).
  • Yu Y , RenQG, ZhangZHet al. Phospho-Rb mediating cell cycle reentry induces early apoptosis following oxygen-glucose deprivation in rat cortical neurons. Neurochem. Res.37(3), 503–511 (2012).
  • Bhaskar K , MillerM, ChludzinskiA, HerrupK, ZagorskiM, LambBT. The PI3K-Akt-mTOR pathway regulates Abeta oligomer induced neuronal cell cycle events. Mol. Neurodegener.4, 14 (2009).
  • Baryawno N , SveinbjornssonB, EksborgS, ChenCS, KognerP, JohnsenJI. Small-molecule inhibitors of phosphatidylinositol 3-kinase/Akt signaling inhibit Wnt/beta-catenin pathway cross-talk and suppress medulloblastoma growth. Cancer Res.70(1), 266–276 (2010).
  • Chung CY , ParkYL, SongYAet al. Knockdown of RON inhibits AP-1 activity and induces apoptosis and cell cycle arrest through the modulation of Akt/FoxO signaling in human colorectal cancer cells. Dig. Dis. Sci.57(2), 371–380 (2012).
  • Fokas E , YoshimuraM, PrevoRet al. NVP-BEZ235 and NVP-BGT226, dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitors, enhance tumor and endothelial cell radiosensitivity. Radiat. Oncol.7(1), 48 (2012).
  • Janku F , WhelerJJ, WestinSNet al. PI3K/AKT/mTOR inhibitors in patients with breast and gynecologic malignancies harboring PIK3CA mutations. J. Clin. Oncol.30(8), 777–782 (2012).
  • Yamada E , SinghR. Mapping autophagy on to your metabolic radar. Diabetes61(2), 272–280 (2012).
  • Clarke PG . Developmental cell death: morphological diversity and multiple mechanisms. Anat. Embryol.181(3), 195–213 (1990).
  • Levine B . Eating oneself and uninvited guests: autophagy-related pathways in cellular defense. Cell120(2), 159–162 (2005).
  • Silva DF , EstevesAR, OliveiraCR, CardosoSM. Mitochondria: the common upstream driver of amyloid-beta and tau pathology in Alzheimer‘s disease. Curr. Alzheimer Res.8(5), 563–572 (2011).
  • Kapoor V , ZaharievaMM, DasSN, BergerMR. Erufosine simultaneously induces apoptosis and autophagy by modulating the Akt-mTOR signaling pathway in oral squamous cell carcinoma. Cancer Lett.319(1), 39–48 (2012).
  • Le XF , MaoW, LuZ, CarterBZ, BastRC Jr. Dasatinib induces autophagic cell death in human ovarian cancer. Cancer116(21), 4980–4990 (2010).
  • Viola G , BortolozziR, HamelEet al. MG-2477, a new tubulin inhibitor, induces autophagy through inhibition of the Akt/mTOR pathway and delayed apoptosis in A549 cells. Biochem. Pharmacol.83(1), 16–26 (2012).
  • Wu YT , TanHL, HuangQ, OngCN, ShenHM. Activation of the PI3K-Akt-mTOR signaling pathway promotes necrotic cell death via suppression of autophagy. Autophagy5(6), 824–834 (2009).
  • Yu L , McpheeCK, ZhengLet al. Termination of autophagy and reformation of lysosomes regulated by mTOR. Nature465(7300), 942–946 (2010).
  • Rong Y , McPheeCK, DengSet al. Spinster is required for autophagic lysosome reformation and mTOR reactivation following starvation. Proc. Natl Acad. Sci. USA108(19), 7826–7831 (2011).
  • Jung CH , JunCB, RoSHet al. ULK-Atg13-FIP200 complexes mediate mTOR signaling to the autophagy machinery. Mol. Biol. Cell20(7), 1992–2003 (2009).
  • Sarkar S , RavikumarB, RubinszteinDC. Autophagic clearance of aggregate-prone proteins associated with neurodegeneration. Methods Enzymol.453, 83–110 (2009).
  • Berger Z , RavikumarB, MenziesFMet al. Rapamycin alleviates toxicity of different aggregate-prone proteins. Hum. Mol. Genet.15(3), 433–442 (2006).
  • Ravikumar B , VacherC, BergerZet al. Inhibition of mTOR induces autophagy and reduces toxicity of polyglutamine expansions in fly and mouse models of Huntington disease. Nat. Genet.36(6), 585–595 (2004).
  • Floto RA , SarkarS, PerlsteinEO, KampmannB, SchreiberSL, RubinszteinDC. Small molecule enhancers of rapamycin-induced TOR inhibition promote autophagy, reduce toxicity in Huntington‘s disease models and enhance killing of mycobacteria by macrophages. Autophagy3(6), 620–622 (2007).
  • Roscic A , BaldoB, CrochemoreC, MarcellinD, PaganettiP. Induction of autophagy with catalytic mTOR inhibitors reduces huntingtin aggregates in a neuronal cell model. J. Neurochem.119(2), 398–407 (2011).
  • Fox JH , ConnorT, ChopraVet al. The mTOR kinase inhibitor Everolimus decreases S6 kinase phosphorylation but fails to reduce mutant huntingtin levels in brain and is not neuroprotective in the R6/2 mouse model of Huntington‘s disease. Mol. Neurodegeneration5, 26 (2010).
  • Hyrskyluoto A , ReijonenS, KivinenJ, LindholmD, KorhonenL. GADD34 mediates cytoprotective autophagy in mutant huntingtin expressing cells via the mTOR pathway. Exp. Cell Res.318(1), 33–42 (2012).
  • Maiese K , ChongZZ, HouJ, ShangYC. New strategies for Alzheimer‘s disease and cognitive impairment. Oxid. Med. Cell Longev.2(5), 279–289 (2009).
  • Slipczuk L , BekinschteinP, KatcheC, CammarotaM, IzquierdoI, MedinaJH. BDNF activates mTOR to regulate GluR1 expression required for memory formation. PLoS ONE4(6), e6007 (2009).
  • Griffin RJ , MoloneyA, KelliherMet al. Activation of Akt/PKB, increased phosphorylation of Akt substrates and loss and altered distribution of Akt and PTEN are features of Alzheimer‘s disease pathology. J. Neurochem.93(1), 105–117 (2005).
  • An WL , CowburnRF, LiLet al. Up-regulation of phosphorylated/activated p70 S6 kinase and its relationship to neurofibrillary pathology in Alzheimer‘s disease. Am. J. Pathol.163(2), 591–607 (2003).
  • Paccalin M , Pain-BarcS, PluchonCet al. Activated mTOR and PKR kinases in lymphocytes correlate with memory and cognitive decline in Alzheimer‘s disease. Dement. Geriatr. Cogn. Disord.22(4), 320–326 (2006).
  • Ma T , HoefferCA, Capetillo-ZarateEet al. Dysregulation of the mTOR pathway mediates impairment of synaptic plasticity in a mouse model of Alzheimer‘s disease. PLoS ONE5(9), e12845 (2010).
  • Lee ST , ChuK, ParkJEet al. Erythropoietin improves memory function with reducing endothelial dysfunction and amyloid-beta burden in Alzheimer‘s disease models. J. Neurochem.120(1), 115–124 (2012).
  • Lafay-Chebassier C , PaccalinM, PageGet al. mTOR/p70S6k signalling alteration by Abeta exposure as well as in APP-PS1 transgenic models and in patients with Alzheimer‘s disease. J. Neurochem.94(1), 215–225 (2005).
  • Chano T , OkabeH, HuletteCM. RB1CC1 insufficiency causes neuronal atrophy through mTOR signaling alteration and involved in the pathology of Alzheimer‘s diseases. Brain Res.1168, 97–105 (2007).
  • Malagelada C , RyuEJ, BiswasSC, Jackson-LewisV, GreeneLA. RTP801 is elevated in Parkinson brain substantia nigral neurons and mediates death in cellular models of Parkinson‘s disease by a mechanism involving mammalian target of rapamycin inactivation. J. Neurosci.26(39), 9996–10005 (2006).
  • Deyoung MP , HorakP, SoferA, SgroiD, EllisenLW. Hypoxia regulates TSC1/2-mTOR signaling and tumor suppression through REDD1-mediated 14-13-3 shuttling. Genes Dev.22(2), 239–251 (2008).
  • Malagelada C , JinZH, Jackson-LewisV, PrzedborskiS, GreeneLA. Rapamycin protects against neuron death in in vitro and in vivo models of Parkinson‘s disease. J. Neurosci.30(3), 1166–1175 (2010).
  • Imai Y , GehrkeS, WangHQet al. Phosphorylation of 4E-BP by LRRK2 affects the maintenance of dopaminergic neurons in Drosophila. Embo J.27(18), 2432–2443 (2008).
  • Tain LS , MortiboysH, TaoRN, ZivianiE, BandmannO, WhitworthAJ. Rapamycin activation of 4E-BP prevents parkinsonian dopaminergic neuron loss. Nat. Neurosci.12(9), 1129–1135 (2009).
  • Santini E , HeimanM, GreengardP, ValjentE, FisoneG. Inhibition of mTOR signaling in Parkinson‘s disease prevents L-DOPA-induced dyskinesia. Sci. Signal.2(80), ra36 (2009).
  • Crews L , SpencerB, DesplatsPet al. Selective molecular alterations in the autophagy pathway in patients with Lewy body disease and in models of alpha-synucleinopathy. PLoS ONE5(2), e9313 (2010).
  • Holmes GL , StafstromCE. Tuberous sclerosis complex and epilepsy: recent developments and future challenges. Epilepsia48(4), 617–630 (2007).
  • Waltereit R , WelzlH, DichgansJ, LippHP, SchmidtWJ, WellerM. Enhanced episodic-like memory and kindling epilepsy in a rat model of tuberous sclerosis. J. Neurochem.96(2), 407–413 (2006).
  • Zeng LH , XuL, GutmannDH, WongM. Rapamycin prevents epilepsy in a mouse model of tuberous sclerosis complex. Ann. Neurol.63(4), 444–453 (2008).
  • Zeng LH , RensingNR, WongM. The mammalian target of rapamycin signaling pathway mediates epileptogenesis in a model of temporal lobe epilepsy. J. Neurosci.29(21), 6964–6972 (2009).
  • Buckmaster PS , IngramEA, WenX. Inhibition of the mammalian target of rapamycin signaling pathway suppresses dentate granule cell axon sprouting in a rodent model of temporal lobe epilepsy. J. Neurosci.29(25), 8259–8269 (2009).
  • Balduini W , CarloniS, BuonocoreG. Autophagy in hypoxia-ischemia induced brain injury. J. Matern. Fetal Neonatal Med.25(Suppl. 1), 30–34 (2012).
  • Shi GD , OuyangYP, ShiJG, LiuY, YuanW, JiaLS. PTEN deletion prevents ischemic brain injury by activating the mTOR signaling pathway. Biochem. Biophys. Res. Commun.404(4), 941–945 (2011).
  • Zhang W , KhatibiNH, Yamaguchi-OkadaMet al. Mammalian target of rapamycin (mTOR) inhibition reduces cerebral vasospasm following a subarachnoid hemorrhage injury in canines. Exp. Neurol.233(2), 799–806 (2012).
  • Erlich S , AlexandrovichA, ShohamiE, Pinkas-KramarskiR. Rapamycin is a neuroprotective treatment for traumatic brain injury. Neurobiol. Dis.26(1), 86–93 (2007).
  • Sekiguchi A , KannoH, OzawaH, YamayaS, ItoiE. Rapamycin promotes autophagy and reduces neural tissue damage and locomotor impairment after spinal cord injury in mice. J. Neurotrauma29(5), 946–956 (2012).
  • Sheng B , LiuJ, LiGH. Metformin preconditioning protects Daphnia pulex from lethal hypoxic insult involving AMPK, HIF and mTOR signaling. Comp. Biochem. Physiol. B Biochem. Mol. Biol.163(1), 51–58 (2012).
  • Koh PO . Melatonin prevents ischemic brain injury through activation of the mTOR/p70S6 kinase signaling pathway. Neurosci. Lett.444(1), 74–78 (2008).
  • Liu G , DetloffMR, MillerKN, SantiL, HouleJD. Exercise modulates microRNAs that affect the PTEN/mTOR pathway in rats after spinal cord injury. Exp. Neurol.233(1), 447–456 (2012).
  • Sun F , ParkKK, BelinSet al. Sustained axon regeneration induced by co-deletion of PTEN and SOCS3. Nature480(7377), 372–375 (2011).
  • Liu K , LuY, LeeJKet al. PTEN deletion enhances the regenerative ability of adult corticospinal neurons. Nat. Neurosci.13(9), 1075–1081 (2010).
  • Park KK , LiuK, HuYet al. Promoting axon regeneration in the adult CNS by modulation of the PTEN/mTOR pathway. Science322(5903), 963–966 (2008).
  • Hu LY , SunZG, WenYMet al. ATP-mediated protein kinase B Akt/mammalian target of rapamycin mTOR/p70 ribosomal S6 protein p70S6 kinase signaling pathway activation promotes improvement of locomotor function after spinal cord injury in rats. Neuroscience169(3), 1046–1062 (2010).
  • Walker CL , WalkerMJ, LiuNKet al. Systemic bisperoxovanadium activates Akt/mTOR, reduces autophagy, and enhances recovery following cervical spinal cord injury. PLoS ONE7(1), e30012 (2012).
  • Pavel ME , HainsworthJD, BaudinEet al. Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, Phase 3 study. Lancet378(9808), 2005–2012 (2011).
  • Barrett D , BrownVI, GruppSA, TeacheyDT. Targeting the PI3K/AKT/mTOR signaling axis in children with hematologic malignancies. Paediatr. Drugs14(5), 299–316 (2012).
  • Grzybowska-Izydorczyk O , SmolewskiP. mTOR kinase inhibitors as a treatment strategy in hematological malignancies. Future Med. Chem.4(4), 487–504 (2012).
  • Hernandez G , LalH, FidalgoMet al. A novel cardioprotective p38-MAPK/mTOR pathway. Exp. Cell Res.317(20), 2938–2949 (2011).
  • Sinha SS , PhamMX, VagelosRHet al. Effect of rapamycin therapy on coronary artery physiology early after cardiac transplantation. Am. Heart J.155(5), 889.e1–6 (2008).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.